Skip to main content
Top

27-01-2015 | Gestational diabetes | Review | Article

Using Oral Agents to Manage Gestational Diabetes: What Have We Learned?

Journal: Current Diabetes Reports

Authors: Elizabeth Buschur, Florence Brown, Jennifer Wyckoff

Publisher: Springer US

Abstract

Insulin has been the mainstay of treatment of diabetes during pregnancy for decades. Although glyburide and metformin are classified as category B during pregnancy, recent research has suggested that these oral agents alone or in conjunction with insulin may be safe for the treatment of gestational diabetes (GDM). This paper summarizes the data on the use of glyburide and metformin for treatment of GDM.
Literature
3.
Langer O et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–8.CrossRefPubMed
4.
Camelo Castillo W et al. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000–2011. Obstet Gynecol. 2014;123(6):1177–84. doi:10.​1097/​AOG.​0000000000000285​.CrossRefPubMed
5.
Ogunyemi DA et al. Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). Diabet Med. 2011;28(8):976–86.CrossRefPubMed
6.
Tattersall R. Diabetes: the biography. Oxford: Oxford University Press; 2009.
7.
Jackson WP, Campbell GD. Chlorpropamide and perinatal mortality. Br Med J. 1963;2(5373):1652.CrossRefPubMedCentralPubMed
8.
Malins JM et al. Sulphonylurea drugs in pregnancy. Br Med J. 1964;2(5402):187.CrossRefPubMedCentralPubMed
9.
Douglas CP, Richards R. Use of chlorpropamide in the treatment of diabetes in pregnancy. Diabetes. 1967;16(1):60–1.CrossRefPubMed
10.
Notelovitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J. 1971;45(9):226–9.PubMed
11.
Sutherland HW et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Child. 1974;49(4):283–91.CrossRefPubMedCentralPubMed
12.
Sutherland HW et al. Evaluation of chlorpropamide in chemical diabetes diagnosed during pregnancy. Br Med J. 1973;3(5870):9–13.CrossRefPubMedCentralPubMed
13.
Kemball ML et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child. 1970;45(243):696–701.CrossRefPubMedCentralPubMed
14.
Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics. 1968;42(5):824–5.PubMed
15.
Uhrig JD, Hurley RM. Chlorpropamide in pregnancy and transient neonatal diabetes insipidus. Can Med Assoc J. 1983;128(4):368. 370–1.PubMedCentralPubMed
16.
Christesen H, Melander A. Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. Eur J Endocrinol. 1998;138(6):698–701.CrossRefPubMed
18.
Ramos GA et al. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007;27(5):262–7.CrossRefPubMed
19.
Coetzee EJ, Jackson WPU. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract. 1985;1(5):281–7.CrossRefPubMed
20.
Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17(7):507–11.CrossRefPubMed
21.
Elliott BD et al. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165(4 Pt 1):807–12.CrossRefPubMed
22.
Elliott BD et al. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171(3):653–60.CrossRefPubMed
23.
Gedeon C et al. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006;27(11–12):1096–102.CrossRefPubMed
24.
Nanovskaya TN et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med. 2008;21(3):197–207.CrossRefPubMed
25.
Koren G. Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol. 2001;15(3):227–9.CrossRefPubMed
26.
Zharikova OL et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol. 2009;78(12):1483–90.CrossRefPubMedCentralPubMed
27.
Ke AB et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2014;77(3):554–70.CrossRefPubMed
28.
Kraemer J et al. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol. 2006;195(1):270–4.CrossRefPubMed
29.
Pollex EK et al. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos. 2010;38(5):740–4.CrossRefPubMed
30.
Hemauer SJ et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010;202(4):383.e1–7.
31.
Iqbal M et al. Placental drug transporters and their role in fetal protection. Placenta. 2012;33(3):137–42.CrossRefPubMed
32.
Hebert MF et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009;85(6):607–14.CrossRefPubMedCentralPubMed
33.
Lim JM et al. A comparison between the pregnancy outcome of women with gestation diabetes treated with glibenclamide and those treated with insulin. Med J Malays. 1997;52(4):377–81.
34.
Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22(5):403–6.CrossRefPubMed
35.
Jacobson GF et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193(1):118–24.CrossRefPubMed
36.
Rochon M et al. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol. 2006;195(4):1090–4.CrossRefPubMed
37.
Holt RIG et al. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab. 2008;10(10):906–11.CrossRefPubMed
38.
Mathews JE et al. Retrospective cohort study comparing neonatal outcomes of women treated with glyburide or insulin in gestational diabetes: a 5-year experience in a South Indian teaching hospital. Indian J Med Sci. 2011;65(11):476–81.CrossRefPubMed
39.
Yogev Y et al. Glyburide in gestational diabetes—prediction of treatment failure. J Matern Fetal Neonatal Med. 2011;24(6):842–6.CrossRefPubMed
40.
Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol. 2004;24(10):617–22.CrossRefPubMed
41.
Bertini Anna, M., et al., Perinatal outcomes and the use of oral hypoglycemic agents, in Journal of Perinatal Medicine. 2005. p. 519.
42.•
Cheng YW et al. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25(4):379–84. This is a large retrospective study of glyburide use in GDM. It is useful as it illustrates the outcomes of the real life application of glyburide in GDM.
43.
Langer O et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol. 2005;192(1):134–9.CrossRefPubMed
44.
Lain KY et al. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol. 2009;200(5):501.e1–6.
45.
Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res. 2013;39(6):1147–52.CrossRefPubMed
46.
Anjalakshi C et al. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract. 2007;76(3):474–5.CrossRefPubMed
47.•
Zeng Y-c et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis. Adv Med Sci. 2014;59(1):95–101. This is a meta-analysis of RCTs of glyburide versus insulin. Most RCTs on this topic are under-powered to detect differences in neonatal outcomes, hence, the importance of a meta-analysis of the topic.
48.
Wareing M et al. Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries. Placenta. 2006;27(6–7):660–8.CrossRefPubMed
49.
Petty RG, Pearson JD. The influence of hypoglycaemic agents on the growth and metabolism of human endothelial cells. Diabet Med. 1992;9(1):30–7.CrossRefPubMed
50.
Downing SJ, Hollingsworth M. Antagonism of relaxin by glibenclamide in the uterus of the rat in vivo. Br J Pharmacol. 1991;104(1):71–6.CrossRefPubMedCentralPubMed
51.
Ballas J, Moore TR, Ramos GA. Management of diabetes in pregnancy. Curr Diabetes Rep. 2012;12(1):33–42.CrossRef
52.
Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Prac Res Clin Obstet Gynaecol. 2011;25(1):51–63.CrossRef
53.
Cassina, M., et al., First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Human Reproduction Update, 2014.
54.
Rowan JA, Mi GI. A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial). Diabetes Care. 2007;30 Suppl 2:S214–9.CrossRefPubMed
55.
Rowan JA et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed
56.
Feig DS. Metformin therapy for gestational diabetes mellitus: are we there yet? Nat Clin Pract Endocrinol Metab. 2008;4(12):654–5.CrossRefPubMed
57.
Rowan JA et al. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. Diabetes Care. 2010;33(1):9–16.CrossRefPubMedCentralPubMed
58.••
Rowan JA et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84. This is the most recent paper in a very important series by these authors reporting on the use of metformin in GDM and the long-term outcomes on offspring.
59.
Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011;28(9):1082–7.CrossRefPubMed
60.
Hickman MA et al. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol. 2013;30(6):483–90.CrossRefPubMed
61.
Ekpebegh CO et al. A 10-year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med. 2007;24(3):253–8.CrossRefPubMed
62.
Tertti K et al. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud. 2008;5(2):95–101.CrossRefPubMedCentralPubMed
63.
Gandhi P et al. Introduction of metformin for gestational diabetes mellitus in clinical practice: has it had an impact? Eur J Obstet Gynecol Reprod Biol. 2012;160(2):147–50.CrossRefPubMed
64.
Balani J et al. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med. 2009;26(8):798–802.CrossRefPubMed
65.
Mesdaghinia E et al. Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial. Int J Prev Med. 2013;4(3):327–33.PubMedCentralPubMed
66.
Moore LE et al. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010;115(1):55–9.CrossRefPubMed
67.
Silva JC et al. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynecol Obstet. 2010;111(1):37–40.CrossRef
68.
Zarate A et al. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex. 2000;68:42–5.PubMed
69.
Wilton LV et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882–9.CrossRefPubMed